Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
37
BGLC Quote, Financials, Valuation and Earnings
Last price:
$4.08
Seasonality move
:
-13.18%
Day range:
$4.02 - $4.14
52-week range:
$2.01 - $15.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.79x
P/B ratio:
1.09x
Volume:
4.7K
Avg. volume:
141.9K
1-year change:
71.78%
Market cap:
$7.4M
Revenue:
$9.5M
EPS (TTM):
-$1.28
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BGLC
BioNexus Gene Lab Corp.
|
-- | -- | -- | -- | -- |
|
BCPC
Balchem Corp.
|
$258.3M | $1.31 | 8.16% | 24.54% | $191.00 |
|
IOSP
Innospec, Inc.
|
$437.5M | $1.06 | -1.27% | -20.34% | $99.33 |
|
PZG
Paramount Gold Nevada Corp.
|
-- | -$0.02 | -- | -50% | $1.70 |
|
XPL
Solitario Resources Corp.
|
-- | -$0.01 | -- | -64.16% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BGLC
BioNexus Gene Lab Corp.
|
$4.14 | -- | $7.4M | -- | $0.00 | 0% | 0.79x |
|
BCPC
Balchem Corp.
|
$157.46 | $191.00 | $5.1B | 34.47x | $0.96 | 0.61% | 5.07x |
|
IOSP
Innospec, Inc.
|
$78.40 | $99.33 | $1.9B | 98.17x | $0.87 | 2.18% | 1.10x |
|
PZG
Paramount Gold Nevada Corp.
|
$1.24 | $1.70 | $97.2M | -- | $0.00 | 0% | -- |
|
XPL
Solitario Resources Corp.
|
$0.69 | $1.50 | $62.8M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BGLC
BioNexus Gene Lab Corp.
|
2.62% | 3.771 | 1.87% | 7.51x |
|
BCPC
Balchem Corp.
|
11.7% | 0.403 | 3.54% | 1.54x |
|
IOSP
Innospec, Inc.
|
3.64% | 0.502 | 2.56% | 1.77x |
|
PZG
Paramount Gold Nevada Corp.
|
27.01% | 2.031 | 12.18% | 1.08x |
|
XPL
Solitario Resources Corp.
|
0.07% | 0.780 | 0.03% | 17.12x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BGLC
BioNexus Gene Lab Corp.
|
$377.7K | -$810.3K | -28.12% | -28.84% | -31.85% | -$1.2M |
|
BCPC
Balchem Corp.
|
$95.5M | $54.9M | 10.45% | 12.23% | 20.52% | $50.7M |
|
IOSP
Innospec, Inc.
|
$116.7M | $31.1M | -0.09% | -0.1% | 7.04% | $17.2M |
|
PZG
Paramount Gold Nevada Corp.
|
-$95.7K | -$1.5M | -25.69% | -34.36% | -- | -$1.1M |
|
XPL
Solitario Resources Corp.
|
-$18K | -$2M | -20.56% | -20.59% | -- | -$1.7M |
BioNexus Gene Lab Corp. vs. Competitors
-
Which has Higher Returns BGLC or BCPC?
Balchem Corp. has a net margin of -27.87% compared to BioNexus Gene Lab Corp.'s net margin of 15.06%. BioNexus Gene Lab Corp.'s return on equity of -28.84% beat Balchem Corp.'s return on equity of 12.23%.
Company Gross Margin Earnings Per Share Invested Capital BGLCBioNexus Gene Lab Corp.14.85% -$0.39 $7M BCPCBalchem Corp.35.68% $1.24 $1.5B -
What do Analysts Say About BGLC or BCPC?
BioNexus Gene Lab Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Balchem Corp. has an analysts' consensus of $191.00 which suggests that it could grow by 21.3%. Given that Balchem Corp. has higher upside potential than BioNexus Gene Lab Corp., analysts believe Balchem Corp. is more attractive than BioNexus Gene Lab Corp..
Company Buy Ratings Hold Ratings Sell Ratings BGLCBioNexus Gene Lab Corp.0 0 0 BCPCBalchem Corp.1 1 0 -
Is BGLC or BCPC More Risky?
BioNexus Gene Lab Corp. has a beta of 3.791, which suggesting that the stock is 279.054% more volatile than S&P 500. In comparison Balchem Corp. has a beta of 0.992, suggesting its less volatile than the S&P 500 by 0.809%.
-
Which is a Better Dividend Stock BGLC or BCPC?
BioNexus Gene Lab Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Balchem Corp. offers a yield of 0.61% to investors and pays a quarterly dividend of $0.96 per share. BioNexus Gene Lab Corp. pays -- of its earnings as a dividend. Balchem Corp. pays out 22.16% of its earnings as a dividend. Balchem Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BGLC or BCPC?
BioNexus Gene Lab Corp. quarterly revenues are $2.5M, which are smaller than Balchem Corp. quarterly revenues of $267.6M. BioNexus Gene Lab Corp.'s net income of -$709K is lower than Balchem Corp.'s net income of $40.3M. Notably, BioNexus Gene Lab Corp.'s price-to-earnings ratio is -- while Balchem Corp.'s PE ratio is 34.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNexus Gene Lab Corp. is 0.79x versus 5.07x for Balchem Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BGLCBioNexus Gene Lab Corp.0.79x -- $2.5M -$709K BCPCBalchem Corp.5.07x 34.47x $267.6M $40.3M
-
Which has Higher Returns BGLC or IOSP?
Innospec, Inc. has a net margin of -27.87% compared to BioNexus Gene Lab Corp.'s net margin of 2.92%. BioNexus Gene Lab Corp.'s return on equity of -28.84% beat Innospec, Inc.'s return on equity of -0.1%.
Company Gross Margin Earnings Per Share Invested Capital BGLCBioNexus Gene Lab Corp.14.85% -$0.39 $7M IOSPInnospec, Inc.26.41% $0.52 $1.4B -
What do Analysts Say About BGLC or IOSP?
BioNexus Gene Lab Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Innospec, Inc. has an analysts' consensus of $99.33 which suggests that it could grow by 26.7%. Given that Innospec, Inc. has higher upside potential than BioNexus Gene Lab Corp., analysts believe Innospec, Inc. is more attractive than BioNexus Gene Lab Corp..
Company Buy Ratings Hold Ratings Sell Ratings BGLCBioNexus Gene Lab Corp.0 0 0 IOSPInnospec, Inc.2 0 0 -
Is BGLC or IOSP More Risky?
BioNexus Gene Lab Corp. has a beta of 3.791, which suggesting that the stock is 279.054% more volatile than S&P 500. In comparison Innospec, Inc. has a beta of 0.931, suggesting its less volatile than the S&P 500 by 6.907%.
-
Which is a Better Dividend Stock BGLC or IOSP?
BioNexus Gene Lab Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innospec, Inc. offers a yield of 2.18% to investors and pays a quarterly dividend of $0.87 per share. BioNexus Gene Lab Corp. pays -- of its earnings as a dividend. Innospec, Inc. pays out 109.37% of its earnings as a dividend.
-
Which has Better Financial Ratios BGLC or IOSP?
BioNexus Gene Lab Corp. quarterly revenues are $2.5M, which are smaller than Innospec, Inc. quarterly revenues of $441.9M. BioNexus Gene Lab Corp.'s net income of -$709K is lower than Innospec, Inc.'s net income of $12.9M. Notably, BioNexus Gene Lab Corp.'s price-to-earnings ratio is -- while Innospec, Inc.'s PE ratio is 98.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNexus Gene Lab Corp. is 0.79x versus 1.10x for Innospec, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BGLCBioNexus Gene Lab Corp.0.79x -- $2.5M -$709K IOSPInnospec, Inc.1.10x 98.17x $441.9M $12.9M
-
Which has Higher Returns BGLC or PZG?
Paramount Gold Nevada Corp. has a net margin of -27.87% compared to BioNexus Gene Lab Corp.'s net margin of --. BioNexus Gene Lab Corp.'s return on equity of -28.84% beat Paramount Gold Nevada Corp.'s return on equity of -34.36%.
Company Gross Margin Earnings Per Share Invested Capital BGLCBioNexus Gene Lab Corp.14.85% -$0.39 $7M PZGParamount Gold Nevada Corp.-- -$0.06 $43.2M -
What do Analysts Say About BGLC or PZG?
BioNexus Gene Lab Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Paramount Gold Nevada Corp. has an analysts' consensus of $1.70 which suggests that it could grow by 37.1%. Given that Paramount Gold Nevada Corp. has higher upside potential than BioNexus Gene Lab Corp., analysts believe Paramount Gold Nevada Corp. is more attractive than BioNexus Gene Lab Corp..
Company Buy Ratings Hold Ratings Sell Ratings BGLCBioNexus Gene Lab Corp.0 0 0 PZGParamount Gold Nevada Corp.1 0 0 -
Is BGLC or PZG More Risky?
BioNexus Gene Lab Corp. has a beta of 3.791, which suggesting that the stock is 279.054% more volatile than S&P 500. In comparison Paramount Gold Nevada Corp. has a beta of 1.319, suggesting its more volatile than the S&P 500 by 31.91%.
-
Which is a Better Dividend Stock BGLC or PZG?
BioNexus Gene Lab Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Paramount Gold Nevada Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNexus Gene Lab Corp. pays -- of its earnings as a dividend. Paramount Gold Nevada Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BGLC or PZG?
BioNexus Gene Lab Corp. quarterly revenues are $2.5M, which are larger than Paramount Gold Nevada Corp. quarterly revenues of --. BioNexus Gene Lab Corp.'s net income of -$709K is higher than Paramount Gold Nevada Corp.'s net income of -$4.3M. Notably, BioNexus Gene Lab Corp.'s price-to-earnings ratio is -- while Paramount Gold Nevada Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNexus Gene Lab Corp. is 0.79x versus -- for Paramount Gold Nevada Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BGLCBioNexus Gene Lab Corp.0.79x -- $2.5M -$709K PZGParamount Gold Nevada Corp.-- -- -- -$4.3M
-
Which has Higher Returns BGLC or XPL?
Solitario Resources Corp. has a net margin of -27.87% compared to BioNexus Gene Lab Corp.'s net margin of --. BioNexus Gene Lab Corp.'s return on equity of -28.84% beat Solitario Resources Corp.'s return on equity of -20.59%.
Company Gross Margin Earnings Per Share Invested Capital BGLCBioNexus Gene Lab Corp.14.85% -$0.39 $7M XPLSolitario Resources Corp.-- -$0.02 $24.8M -
What do Analysts Say About BGLC or XPL?
BioNexus Gene Lab Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Solitario Resources Corp. has an analysts' consensus of $1.50 which suggests that it could grow by 117.08%. Given that Solitario Resources Corp. has higher upside potential than BioNexus Gene Lab Corp., analysts believe Solitario Resources Corp. is more attractive than BioNexus Gene Lab Corp..
Company Buy Ratings Hold Ratings Sell Ratings BGLCBioNexus Gene Lab Corp.0 0 0 XPLSolitario Resources Corp.2 0 0 -
Is BGLC or XPL More Risky?
BioNexus Gene Lab Corp. has a beta of 3.791, which suggesting that the stock is 279.054% more volatile than S&P 500. In comparison Solitario Resources Corp. has a beta of 0.440, suggesting its less volatile than the S&P 500 by 55.966%.
-
Which is a Better Dividend Stock BGLC or XPL?
BioNexus Gene Lab Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solitario Resources Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNexus Gene Lab Corp. pays -- of its earnings as a dividend. Solitario Resources Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BGLC or XPL?
BioNexus Gene Lab Corp. quarterly revenues are $2.5M, which are larger than Solitario Resources Corp. quarterly revenues of --. BioNexus Gene Lab Corp.'s net income of -$709K is higher than Solitario Resources Corp.'s net income of -$1.9M. Notably, BioNexus Gene Lab Corp.'s price-to-earnings ratio is -- while Solitario Resources Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNexus Gene Lab Corp. is 0.79x versus -- for Solitario Resources Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BGLCBioNexus Gene Lab Corp.0.79x -- $2.5M -$709K XPLSolitario Resources Corp.-- -- -- -$1.9M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 29
Galecto, Inc. [GLTO] is down 12.13% over the past day.
Sell
20
SMX alert for Dec 29
SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.
Sell
11
CDNAF alert for Dec 29
Canadian Tire Corp. Ltd. [CDNAF] is up 11.94% over the past day.
